Director Sinclair Discloses 10b5-1 Sales of Apellis Shares on 09/19/2025
Rhea-AI Filing Summary
Dunlop A. Sinclair, a director of Apellis Pharmaceuticals (APLS), reported multiple dispositions of Apellis common stock on 09/19/2025. Sales include 31,092 shares sold under a Rule 10b5-1 plan at a weighted-average price of $22.95 (execution prices ranged $22.73–$23.27). A separate distribution of 3,837 shares was recorded as a stock distribution for no consideration. The reported holdings after the first two transactions were 68,908 and 65,071 shares, respectively, held indirectly through Epidarex Capital I LP, of which Sinclair is a general partner and may be deemed to have voting and dispositive power. The Form 4 was signed by an attorney-in-fact on behalf of Sinclair.
Positive
- Transactions disclosed under a Rule 10b5-1 plan, indicating a pre-arranged trading mechanism adopted June 20, 2025
- Clear execution pricing provided: weighted-average price $22.95 and range $22.73–$23.27 for the reported sales
- Form 4 filed and signed (attorney-in-fact signature present), meeting SEC reporting requirements
Negative
- Substantial dispositions reported (31,092 shares plus 158,393 shares disposed as listed), representing meaningful reductions in indirect holdings
- Indirect holdings reduced to 68,908 and then 65,071 shares after reported transactions, which may be material to shareholder stake via Epidarex
Insights
TL;DR Insider disposals via a 10b5-1 plan reduced indirect holdings; sales were executed at ~$22.95 weighted average.
These transactions represent programmed dispositions rather than one-off open-market exercises, which can temper immediate governance concerns about information asymmetry. The reported weighted-average sale price of $22.95 and the stated price range provide clear execution details. Investors should note the holdings are indirect via Epidarex, with the reporting person disclaiming direct beneficial ownership beyond pecuniary interest; this affects how to interpret apparent insider commitment levels.
TL;DR Sales occurred under a documented 10b5-1 plan and were disclosed on Form 4, indicating procedural compliance.
The filing explicitly states the use of a Rule 10b5-1 plan adopted June 20, 2025, and provides required detail on execution prices and the nature of indirect ownership through Epidarex. The reporting person disclaims beneficial ownership except for pecuniary interest, and an attorney-in-fact signed the form, which are standard governance disclosures. Documentation appears to follow Section 16 reporting requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 31,092 | $22.95 | $714K |
| Other | Common Stock | 3,837 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 to $23.27, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein. Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.
